Menu Search
Equities

Eurofins-Cerep SA

ALECR:PAR

Eurofins-Cerep SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)21,400.00
  • Today's Change0.00 / 0.00%
  • Shares traded2.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 18 2024 13:32 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Eurofins-Cerep SA's revenues fell -7.47% from 47.63m to 44.07m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 11.52m to 7.64m, a -33.72% decrease.
Gross margin85.01%
Net profit margin17.33%
Operating margin14.38%
Return on assets10.16%
Return on equity12.57%
Return on investment12.22%
More ▼

Growth rates in EUR

Year on year, growth in earnings per share excluding extraordinary items dropped -33.72%. Additionally, five year annualized earnings per share growth ranks highest in its industry.
EPS growth(5 years)14.64
EPS (TTM) vs
TTM 1 year ago		-33.72
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.